Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 13.6a

Immunosuppression Use for Induction, 1998 to 2007

Recipients with Heart-Lung Transplants

  Year of Transplant
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 47 51 48 27 33 29 40 35 31 29
With Immunosuppression Info 45 50 48 26 33 28 38 33 30 27
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 20.0% 16.0% 29.2% 26.9% 15.2% 3.6% 13.2% 12.1% 3.3% 33.3%
OKT3 6.7% 10.0% 6.3% 0.0% 6.1% 3.6% 2.6% 3.0% 0.0% 7.4%
Thymoglobulin 0.0% 4.0% 4.2% 11.5% 3.0% 10.7% 13.2% 3.0% 6.7% 0.0%
Zenapax 0.0% 4.0% 12.5% 7.7% 15.2% 7.1% 18.4% 12.1% 16.7% 11.1%
Simulect 0.0% 0.0% 4.2% 30.8% 18.2% 17.9% 10.5% 24.2% 10.0% 25.9%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 5.3% 9.1% 23.3% 18.5%
No Induction Drugs Recorded 75.6% 66.0% 47.9% 26.9% 42.4% 57.1% 42.1% 39.4% 40.0% 18.5%


Source: OPTN/SRTR Data as of May 1, 2008.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader